Neurocrine Biosciences Inc (LTS:0K6R) Stock News, Headlines & Updates
Neurocrine Biosciences Inc Stock News from GuruFocus
- 1
Aug 16, 2024
Insider Sale: Director William Rastetter Sells 14,250 Shares of Neurocrine Biosciences Inc (NBIX)
GuruFocus Research • 5:01pm
Aug 07, 2024
Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
PRNewswire • 4:01pm
Aug 02, 2024
Neurocrine Biosciences Inc (NBIX) Q2 2024 Earnings Call Transcript Highlights: Strong Sales Growth and Promising Pipeline Developments
GuruFocus Research • 1:02am
Q2 2024 Neurocrine Biosciences Inc Earnings Call Transcript
GuruFocus Research • 11:12pm
Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight
GuruFocus Research • 11:05pm
Aug 01, 2024
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
PRNewswire • 7:00am
Neurocrine Biosciences (NBIX) Q2 2024 Earnings: EPS of $0.63, Revenue Surpasses Estimates at $590.2 Million
GuruFocus Research • 6:31am
Jul 18, 2024
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
PRNewswire • 8:00am
Jul 11, 2024
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
PRNewswire • 4:00pm
Jul 01, 2024
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
PRNewswire • 7:00am
Jun 03, 2024
Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
PRNewswire • 8:00am
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
PRNewswire • 7:00am
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
PRNewswire • 7:00am
May 29, 2024
Neurocrine Biosciences to Participate at Investor Conferences in June
PRNewswire • 4:00pm
May 28, 2024
Neurocrine Biosciences Announces CEO Succession Plan
PRNewswire • 4:00pm
- 1
Show
Entries
Headlines
Total 0- 1
No recent news